Abstracts

PHENOTYPIC DORAVIRINE SUSCEPTIBILITY AFTER NNRTI EXPOSURE IN THE PRESTIGIO REGISTRY

Doravirine (DOR) is an NNRTI recently licensed for first-line ART showing superior genetic barrier to resistance and partial cross-resistance with older NNRTI. We investigated susceptibility to DOR in patients with documented 4-class drug-resistance to NRTI, NNRTI, PI, INSTI (4CR), enrolled in the Italian PRESTIGIO Registry. Recombinant HIV-1 expressing patient derived PR-RT were generated from plasma…